Opendata, web and dolomites

VANGUARD SIGNED

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VANGUARD project word cloud

Explore the words cloud of the VANGUARD project. It provides you a very rough idea of what is the project "VANGUARD" about.

sources    therapies    medicinal    clinical    urgent    rapid    pd    implantation    xenogeneic    cell    ngo    majority    destruction    inflammatory    stem    revascularization    locally    haec    l1    graft    transplantation    haecs    construct    implantability    mice    managed    vivo    cells    vanguard    chronic    amniotic    completion    blood    membrane    million    langerhans    producing    vast    release    diabetes    safety    genome    hydrogel    overexpress    limited    confer    boecs    atmp    delivered    consists    forty    academic    insulin    matrix    outgrowth    hla    scientists    social    worldwide    immune    individuals    disease    immunomodulatory    biocompatibility    pancreas    vitro    anti    model    epithelial    smes    constructs    bioartificial    organoids    islet    potency    devastating    translational    cd47    molecules    ethical    therapeutic    assembling    suffer    diabetic    reconstituted    therapy    infinite    endothelial    larger    utilizing    components    patients    replacement    extracellular    complications    accessibility    edited    protection    mechanical    expertise    human    beta   

Project "VANGUARD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE GENEVE 

Organization address
address: RUE DU GENERAL DUFOUR 24
city: GENEVE
postcode: 1211
website: www.unige.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 6˙844˙625 €
 EC max contribution 6˙844˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 1˙995˙946.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙049˙500.00
3    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO IT (VERCELLI) participant 936˙875.00
4    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 804˙375.00
5    KUGELMEIERS AG CH (ERLENBACH) participant 701˙250.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 523˙812.00
7    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 393˙116.00
8    ACCELOPMENT AG CH (ZUERICH) participant 384˙750.00
9    EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION NL (AMSTERDAM) participant 55˙000.00

Map

 Project objective

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VANGUARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VANGUARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More